

NATIONAL INSTITUTE FOR HEALTH CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed:				
Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	Proposal:	Proposal made by:	Action taken: Removed/Added/Not included/Noted	Justification:
1.	Celltrion Healthcare	NICE Secretariat	Added	This organisation has an area of interest directly related to this appraisal and meets the selection criteria to participate in this appraisal. Celltrion Healthcare has been added to the matrix of consultees and commentators as a 'manufacturer'.

National Institute for Health and Clinical Excellence

Consultation comments on the provisional matrix for the technology appraisal of **infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)**

Issue date: November, 2013

Appendix D - NICE's response to consultee and commentator comments on the draft scope and provisional matrix

2.	Hospira UK	NICE Secretariat	Added	This organisation has an area of interest directly related to this appraisal and meets the selection criteria to participate in this appraisal. Hospira UK has been added to the matrix of consultees and commentators as a 'manufacturer'.
3.	Independent Age (formerly Counsel and Care)	Independent Age	Removed	Independent Age (formerly Counsel and Care) have asked not to be included in matrices relating to clinical issues. This is a charity that focuses largely on a more social than a medical model of care. Independent Age has been removed from the matrix of consultees and commentators under 'patient groups'
4.	Crohn's in Childhood Research Association (CICRA)	Merck Sharp and Dohme	Added	This organisation has an area of interest directly related to this appraisal and meets the selection criteria to participate in this appraisal. CICRA has been added to the matrix of consultees and commentators as a 'research group.'

National Institute for Health and Clinical Excellence

Consultation comments on the provisional matrix for the technology appraisal of **infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)**

Issue date: November, 2013